Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Fredenburgh

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Advances in Experimental Medicine and Biology|January 1, 1997
Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexesD L Becker, J C Fredenburgh, A R Stafford, et al.
The Journal of Biological Chemistry|February 26, 1999
Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor IID L Becker, J C Fredenburgh, A R Stafford, et al.
Circulation|January 7, 1997
Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfateB Cosmi, J C Fredenburgh, J Rischke, et al.
Thrombosis and Haemostasis|February 28, 2014
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbitsJ W Yau, P Liao, J C Fredenburgh, et al.
The Journal of Biological Chemistry|September 6, 2000
Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activatorR J Stewart, J C Fredenburgh, J A Rischke, et al.
The Journal of Biological Chemistry|June 30, 1995
The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge regionA J Horrevoets, A E Smilde, J C Fredenburgh, et al.
The Journal of Biological Chemistry|April 11, 2001
Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparinP C Liaw, D L Becker, A R Stafford, et al.
Thrombosis and Haemostasis|April 20, 2001
Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasminA Y Lee, J C Fredenburgh, R J Stewart, et al.
The Journal of Biological Chemistry|September 17, 1999
Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor IIP C Liaw, R C Austin, J C Fredenburgh, et al.
Circulation|February 9, 1999
Vasoflux, a new anticoagulant with a novel mechanism of actionJ I Weitz, E Young, M Johnston, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Advances in Experimental Medicine and Biology|January 1, 1997
Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexesD L Becker, J C Fredenburgh, A R Stafford, et al.
The Journal of Biological Chemistry|February 26, 1999
Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor IID L Becker, J C Fredenburgh, A R Stafford, et al.
Circulation|January 7, 1997
Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfateB Cosmi, J C Fredenburgh, J Rischke, et al.
Thrombosis and Haemostasis|February 28, 2014
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbitsJ W Yau, P Liao, J C Fredenburgh, et al.
The Journal of Biological Chemistry|September 6, 2000
Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activatorR J Stewart, J C Fredenburgh, J A Rischke, et al.
The Journal of Biological Chemistry|June 30, 1995
The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge regionA J Horrevoets, A E Smilde, J C Fredenburgh, et al.
The Journal of Biological Chemistry|April 11, 2001
Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparinP C Liaw, D L Becker, A R Stafford, et al.
Thrombosis and Haemostasis|April 20, 2001
Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasminA Y Lee, J C Fredenburgh, R J Stewart, et al.
The Journal of Biological Chemistry|September 17, 1999
Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor IIP C Liaw, R C Austin, J C Fredenburgh, et al.
Circulation|February 9, 1999
Vasoflux, a new anticoagulant with a novel mechanism of actionJ I Weitz, E Young, M Johnston, et al.
Pageof 3